Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Sohn

Showing results (151-160 of 253) with videos related to

Pageof 26
Sort By:
Annals of Surgical Oncology|July 31, 2015
Predictors of Residual Tumor in Breast-Conserving TherapyMichelle G Rath, Lorenz Uhlmann, Joerg Heil, et al.
Plos One|November 7, 2013
Plasma microRNA panel for minimally invasive detection of breast cancerKatarina Cuk, Manuela Zucknick, Dharanija Madhavan, et al.
Breast Cancer Research and Treatment|January 15, 2013
CD24 polymorphisms in breast cancer: impact on prognosis and riskKatharina Buck, Sarah Hug, Petra Seibold, et al.
Oncoimmunology|March 5, 2016
Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patientsCarlo Fremd, Stefan Stefanovic, Philipp Beckhove, et al.
BMC Cancer|June 17, 2011
Simultaneous integrated boost for adjuvant treatment of breast cancer--intensity modulated vs. conventional radiotherapy: the IMRT-MC2 trialVasileios Askoxylakis, Alexandra D Jensen, Matthias F Häfner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?Joerg Heil, Benedikt Schaefgen, Peter Sinn, et al.
International Journal of Cancer|August 29, 2012
Circulating microRNAs in plasma as early detection markers for breast cancerKatarina Cuk, Manuela Zucknick, Jörg Heil, et al.
Oncotargets and Therapy|July 29, 2016
Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trialAlexandra von Au, Eva Milloth, Ingo Diel, et al.
BMC Cancer|May 15, 2015
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patientsMarkus Wallwiener, Andreas Daniel Hartkopf, Sabine Riethdorf, et al.
Archives of Gynecology and Obstetrics|February 9, 2017
Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center studyAlexandra von Au, Mona Klotzbuecher, Lorenz Uhlmann, et al.
Pageof 26

Showing results (151-160 of 253) with videos related to

Sort By:
Pageof 26
Annals of Surgical Oncology|July 31, 2015
Predictors of Residual Tumor in Breast-Conserving TherapyMichelle G Rath, Lorenz Uhlmann, Joerg Heil, et al.
Plos One|November 7, 2013
Plasma microRNA panel for minimally invasive detection of breast cancerKatarina Cuk, Manuela Zucknick, Dharanija Madhavan, et al.
Breast Cancer Research and Treatment|January 15, 2013
CD24 polymorphisms in breast cancer: impact on prognosis and riskKatharina Buck, Sarah Hug, Petra Seibold, et al.
Oncoimmunology|March 5, 2016
Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patientsCarlo Fremd, Stefan Stefanovic, Philipp Beckhove, et al.
BMC Cancer|June 17, 2011
Simultaneous integrated boost for adjuvant treatment of breast cancer--intensity modulated vs. conventional radiotherapy: the IMRT-MC2 trialVasileios Askoxylakis, Alexandra D Jensen, Matthias F Häfner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?Joerg Heil, Benedikt Schaefgen, Peter Sinn, et al.
International Journal of Cancer|August 29, 2012
Circulating microRNAs in plasma as early detection markers for breast cancerKatarina Cuk, Manuela Zucknick, Jörg Heil, et al.
Oncotargets and Therapy|July 29, 2016
Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trialAlexandra von Au, Eva Milloth, Ingo Diel, et al.
BMC Cancer|May 15, 2015
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patientsMarkus Wallwiener, Andreas Daniel Hartkopf, Sabine Riethdorf, et al.
Archives of Gynecology and Obstetrics|February 9, 2017
Impact of reproductive factors on breast cancer subtypes in postmenopausal women: a retrospective single-center studyAlexandra von Au, Mona Klotzbuecher, Lorenz Uhlmann, et al.
Pageof 26